FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1027-1030 September 26, 2002 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective by Wenzel, R. P. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

A new hypothesis with implications for the treatment of sepsis has recently been tested — the hypothesis that part of the pathophysiology of sepsis is caused by unrestricted or inappropriate coagulation in the microcirculation. Three agents that block coagulation at different stages have now been evaluated in large, multicenter trials as adjunctive therapy for sepsis. Neither antithrombin III nor tissue-factor-pathway inhibitor was effective in patients with severe sepsis or septic shock.^1,2 In contrast, treatment with activated protein C (drotrecogin alfa [activated]) was associated with a significant reduction in 28-day mortality. Of the patients who received activated protein C, 24.7 percent . . . [Full Text of this Article]

The Two Phases of the Activated Protein C Trial

Subgroups and Restriction to Use in High-Risk Patients

Risk of Serious Hemorrhage

Conclusions

Related Letters:

Activated Protein C for Severe Sepsis
Ely E. W., Bernard G. R., Vincent J.-L.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:1035-1036, Sep 26, 2002. Correspondence

This article has been cited by other articles:

• Bouchama, A., Kunzelmann, C., Dehbi, M., Kwaasi, A., Eldali, A., Zobairi, F., Freyssinet, J.-M., de Prost, D. (2008). Recombinant Activated Protein C Attenuates Endothelial Injury and Inhibits Procoagulant Microparticles Release in Baboon Heatstroke. Arterioscler. Thromb. Vasc. Bio. 28: 1318-1325 [Abstract] [Full Text]  
• Friedrich, J. O., LaRosa, S. P., Baillie, J.K., Murray, G., Abraham, E., Laterre, P.-F. (2006). Drotrecogin Alfa (Activated) in Severe Sepsis. NEJM 354: 94-96 [Full Text]  
• Rudis, M. I., Rowland, K. L. (2005). Current Concepts in Severe Sepsis and Septic Shock. Journal of Pharmacy Practice 18: 351-362 [Abstract]  
• Parrillo, J. E. (2005). Severe sepsis and therapy with activated protein C.. NEJM 353: 1398-1400 [Full Text]  
• Guidet, B., Aegerter, P., Gauzit, R., Meshaka, P., Dreyfuss, D., on behalf of the CUB-Rea Study Group, (2005). Incidence and Impact of Organ Dysfunctions Associated With Sepsis. Chest 127: 942-951 [Abstract] [Full Text]  
• Gropper, M. A. (2004). Evidence-Based Management of Critically Ill Patients: Analysis and Implementation. Anesth. Analg. 99: 566-572 [Abstract] [Full Text]  
• Graham, P. L., Cook, D. A. (2004). Prediction of Risk of Death Using 30-Day Outcome: A Practical End Point for Quality Auditing in Intensive Care. Chest 125: 1458-1466 [Abstract] [Full Text]  
• Easby, J., Greaves, I. (2004). Current concepts in the diagnosis and management of trauma-related sepsis. Trauma 6: 1-11 [Abstract]  
• Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A. L., Beale, R., Svoboda, P., Laterre, P. F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettila, V., Artigas, A., Percell, S. R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J. C., Creasey, A. A. (2003). Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis: A Randomized Controlled Trial. JAMA 290: 238-247 [Abstract] [Full Text]  
• Angus, D. C., Crowther, M. A. (2003). Unraveling Severe Sepsis: Why Did OPTIMIST Fail and What's Next?. JAMA 290: 256-258 [Full Text]  
• Morreim, E. H. (2003). A Dose of Our Own Medicine: Alternative Medicine, Conventional Medicine, and the Standards of Science. J Law Med Ethics 31: 222-235  
• De Vriese, A. S. (2003). Prevention and Treatment of Acute Renal Failure in Sepsis. J. Am. Soc. Nephrol. 14: 792-805 [Full Text]  
• Hotchkiss, R. S., Karl, I. E. (2003). The Pathophysiology and Treatment of Sepsis. NEJM 348: 138-150 [Full Text]  
• (2002). Activated Protein C -- How Should We Use It to Treat Sepsis?. JWatch Infect. Diseases 2002: 3-3 [Full Text]  
• (2002). Debate on Xigris Heats Up. JWatch General 2002: 4-4 [Full Text]  
• Siegel, J. P. (2002). Assessing the Use of Activated Protein C in the Treatment of Severe Sepsis. NEJM 347: 1030-1034 [Full Text]  
• Ely, E. W., Bernard, G. R., Vincent, J.-L. (2002). Activated Protein C for Severe Sepsis. NEJM 347: 1035-1036 [Full Text]